ArticleJTO clinical and research reports2024

Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 Study.

Matthew G Krebs et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.